Hepatitis C: Australia Refuses to Subsidize Costly New Drug; CBCD Reviews a Report

Share Article

“Australia is the only developed country in the world that has not agreed to subsidize (sofosbuvir) the new $70,000 treatment for Hepatitis C,” according to a report published on ABC.net.au on October 24, 2014. (1) The CBCD reviews the report and recommends two natural HCV remedies.

News Image
We believe that poor, HCV positive individuals in Australia, and elsewhere, need an effective and safe remedy. We want doctors to become aware of Novirin and Gene-Eden-VIR.” – Greg Bennett, CBCD

“Infected with the hepatitis C virus (HCV)? The CBCD recommends taking Novirin or Gene-Eden-VIR.” - Greg Bennett, CBCD

The anti-hepatitis C drug Sofosbuvir, which is made by the pharmaceutical giant, Gilead Sciences (GILD), will not be subsidized by the Australian government. The Pharmaceutical Benefits Advisory Committee (PBAC) argued that “the costs were too high to treat Australia's 250,000 Hepatitis C sufferers,” and promised to review the decision in a year, hoping that by then the drug company will have set a more reasonable price. (1) Dr. Miriam Levy said that the government’s decision to refuse subsidies of Sofusbuvir had effectively “delivered a death sentence to up to 50,000 Australians who would die from the disease in the next few years.” (1) Dr. Levy is the director of gastroenterology at Sydney's Liverpool Hospital. She continued, saying that “while 80 per cent of Australia's sufferers can probably afford to wait a few years until cheaper treatments become available, those who were already heading towards liver failure need the treatment now.” (1) In other words, Dr. Levy is arguing that the Australian government needs to spend close to $4 billion U.S. dollars to save these 50,000 HCV patients.

“We would like to ask Dr. Levy where this money will come from? Since the health budget is limited, how many other patients will have to die so that Dr. Levy can save these 50,000 patients? Every decision is a trade-off. Something Dr. Levy fails to understand.” - Greg Bennett, CBCD

The CBCD would like to recommend that doctors like Dr. Levy, learn about Novirin and Gene-Eden-VIR. These natural products have a formula shown to reduce HCV symptoms in two separate post-marketing clinical studies.

Click to learn more about HCV symptoms.

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against the hepatitis C virus, and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with HCV … reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (2) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (2)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Forbes.com notes that Sofosbuvir “offers a higher cure rate with less toxicity and a shorter duration for treatment than a pair of medicines from Merck and Vertex Pharmaceuticals that was approved two years ago, which explains the enthusiasm on Wall Street, where sofosbuvir pricing is expected to reach $80,000 to $90,000 per patient in the US.” (See Forbes.com, from November 11, 2013) (3)

According to Andrew Hill, one of the researchers on Sofosbuvir, “If the current high prices continue, it is likely that very few people will be treated … it is only by lowering the prices, and treating more people, that there could be a real change.” (3)

What treatments are available against the HCV virus?

Until recently, “the combination of a pegylated interferon (IFN)-α and ribavirin (was) the standard treatment for chronic HCV infections. This combination is effective in about 80% of the individuals infected with the HCV genotype 2 or 3, and in about 40% – 50% in those infected with genotype 1 or 4. Lately, two new drugs were approved, telaprevir and boceprevir, with better results. However, the combinations of pegylated interferon (IFN)-α and ribavirin and telaprevir or boceprevir are associated with additional side effects, increased costs, and more complex treatment strategies.” (2)

“We believe that poor, HCV positive individuals in Australia, and elsewhere, need an effective and safe remedy. We want doctors to become aware of Novirin and Gene-Eden-VIR, which are two effective remedies designed to be affordable by most individuals.” – Greg Bennett, CBCD

Click to read the study: Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study

Click to read the study: Gene-Eden-VIR Decreased Physical and Mental Fatigue in a Post Marketing Clinical Study That Followed FDA Guidelines; Results Support Microcompetition Theory

Click to learn more about Novirin and hepatitis C and Gene-Eden-VIR and hepatitis C.


(1) ABC.net.au - Cornwall, D. Australia's rejection of costly new treatment sofosbuvir a 'death sentence for Hepatitis C sufferers.' Published October 24, 2014.
(2) Gene-Eden-VIR is Antiviral: Results of a Post marketing clinical study. Published in September 2013. http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VE44nyKUf90

(3) Forbes.com - Silverman, E. Will The New Hepatitis C Drugs Trigger A Battle Over Cost? Published on November 11, 2013.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Greg Bennett
+1 5852509999
Email >
Visit website